May 1, 2003
Citations
0
Influential Citations
0
Citations
Journal
Expert Opinion on Therapeutic Patents
Abstract
Two patents claim structurally novel 4-(2-arylindol-3-yl) butanoic acid derivatives that are active as CXC chemokine receptor-2 (CXCR2) antagonists. The claimed compounds differ in the indole 5-substituent, either having a substituted phenyl ring or a nitrile group. The compounds are claimed to be useful in the treatment of a broad range of inflammatory disease.